Bullous Pemphigoid Market

Market Overview:

The 7 major bullous pemphigoid markets reached a value of US$ 245.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,379.3 Million by 2034, exhibiting a growth rate (CAGR) of 16.99% during 2024-2034.

The bullous pemphigoid market has been comprehensively analyzed in IMARC's new report titled "Bullous Pemphigoid Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Bullous pemphigoid refers to a chronic autoimmune disorder that majorly affects the skin and mucous membranes, causing the formation of fluid-filled blisters, or bullae. It usually occurs when the immune system mistakenly attacks a protein named collagen, which is present in the skin and mucous membranes. This ailment usually starts with an itchy, raised rash, but as the condition develops, large blisters can form on the skin. These blisters typically appear on the arms, legs, and torso but can also affect the mouth, eyes, and genital region. Individuals suffering from bullous pemphigoid may experience intense burning, stinging, painful sores, along with redness and swelling of the affected area. The diagnosis of this disease requires a detailed evaluation of the patient’s symptoms and medical history. Blood tests and immunofluorescence testing of skin and serum are also utilized to validate abnormalities within the body. The healthcare provider may perform a biopsy that involves the removal of a small skin region and its laboratory examination.

The increasing cases of immune-mediated diseases that can trigger inflammation due to overactivation of the antibodies within the body are primarily driving the bullous pemphigoid market. Furthermore, the rising prevalence of exposure to ultraviolet light and ionizing radiation, resulting in premature aging and damage to the skin, is also propelling the market growth. In addition to this, the escalating utilization of various steroid-sparing drugs, including azathioprine, dapsone, mycophenolate mofetil, etc., which can ease symptoms like pain and itching, is further creating a positive outlook for the market. Moreover, the inflating usage of enzyme-linked immunosorbent assay (ELISA) for diagnosis of the ailment and to determine response to treatment is also bolstering the market growth. Apart from this, the emerging popularity of low-level laser therapies, since they are less uncomfortable and offer faster wound healing as compared to other conventional medications, is acting as another significant growth-inducing factor. Additionally, the widespread adoption of a monoclonal antibody that targets mast cell degranulation, which reduces the formation of blisters, is expected to drive the bullous pemphigoid market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the bullous pemphigoid market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for bullous pemphigoid and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the bullous pemphigoid market in any manner.

Recent Developments:

• In February 2024, Nuvig Therapeutics, Inc. announced the first human dosage of NVG-2089, a patented medication being developed to treat patients with inflammatory myopathies and severe dermatologic autoimmune illnesses. Nuvig also reported that the FDA issued fast track designation (FTD) to NVG-2089's development in bullous pemphigoid.
• In December 2023, Argenx SE reported the topline results of the ADDRESS trial, which evaluated efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with pemphigus vulgaris (PV) and pemphigus foliaceus (PF). According to the ADDRESS findings, there was no significant difference in the proportion of PV patients who achieved the primary endpoint of complete remission on a minimal dosage of steroids (CRmin) between efgartigimod SC and placebo.

Key Highlights:

• Bullous pemphigoid is the most frequent autoimmune subepidermal blistering condition, accounting for 80% of subepidermal immunobullous instances.
• Bullous pemphigoid affects one in every 4,000 people in Europe.
• This condition primarily affects the elderly, with an average age of 80 years, and is strongly related to neurological diseases.
• While the annual incidence of bullous pemphigoid has been reported to be between 2.4 and 23 cases per million in the general population, it increases exponentially to 190-312 cases per million in those older than 80 years.
• Most investigations showed a clear female preponderance, with a female-to-male ratio ranging from 1.04 to 5.1.

Drugs:

Kenketu Glovenin I (Immune globulin) is a prescription drug used for the treatment of bullous pemphigoid in patients who are inadequately responsive to corticosteroids. It is a lyophilized powder solution for injection. Each vial holds 500, 2500, or 5000 mg of polyethylene glycol-treated human normal immunoglobulin G.

Efgartigimod PH20 SC is a subcutaneous formulation containing efgartigimod alfa, a human IgG1 antibody fragment marketed for intravenous usage as VYVGART, and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE drug delivery technology that enables subcutaneous injection of biologics. It helps to reduce circulating IgG levels by attaching to the neonatal Fc receptor (FcRn).

AKST4290 is an antagonist of the G protein-coupled C-C chemokine receptor type 3 (CCR3). Blocking CCR3 is likely to have a wide anti-inflammatory and immune-modulatory effect. This therapeutic candidate is administered orally.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the bullous pemphigoid market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the bullous pemphigoid market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current bullous pemphigoid marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the bullous pemphigoid market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the bullous pemphigoid market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the bullous pemphigoid market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of bullous pemphigoid across the seven major markets?
• What is the number of prevalent cases (2018-2034) of bullous pemphigoid by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of bullous pemphigoid by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with bullous pemphigoid across the seven major markets?
• What is the size of the bullous pemphigoid patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of bullous pemphigoid?
• What will be the growth rate of patients across the seven major markets?
   

Bullous Pemphigoid: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for bullous pemphigoid drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the bullous pemphigoid market?
• What are the key regulatory events related to the bullous pemphigoid market?
• What is the structure of clinical trial landscape by status related to the bullous pemphigoid market?
• What is the structure of clinical trial landscape by phase related to the bullous pemphigoid market?
• What is the structure of clinical trial landscape by route of administration related to the bullous pemphigoid market?